Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
Status:
Terminated
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and
ceftazidime, administered intravenously as either thrice daily short infusions or 24 h
continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary
PA infection. In conventional treatment regimens, ceftazidime is administered in the form of
thrice daily short infusions, but pharmacodynamic considerations suggest that continuous
infusion could be more effective.
Phase:
Phase 4
Details
Lead Sponsor:
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Collaborators:
Baxter Healthcare Corporation GlaxoSmithKline Roche Pharma AG Vaincre la Mucoviscidose